Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Registry for Subjects With Cirrhosis Who Achieve a Sustained Virologic Response Following Treatment With a Sofosbuvir-Based Regimen Without Interferon for Chronic Hepatitis C Infection

Next Previous
Search
Trial Profile

A Registry for Subjects With Cirrhosis Who Achieve a Sustained Virologic Response Following Treatment With a Sofosbuvir-Based Regimen Without Interferon for Chronic Hepatitis C Infection

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 29 Dec 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Sofosbuvir (Primary) ; Ledipasvir/sofosbuvir; Sofosbuvir/velpatasvir; Sofosbuvir/velpatasvir/voxilaprevir; Voxilaprevir
  • Indications Hepatitis C
  • Focus Therapeutic Use
  • Sponsors Gilead Sciences

Most Recent Events

  • 14 Nov 2023 Results (n=132) assessing risk factors of HCC and characterize the natural history of HCC development in patients who have achieved SVR with sofosbuvir-based direct-acting antiviral therapy (DAA presented at The Liver Meeting 2023: 74th Annual Meeting of the American Association for the Study of Liver Diseases
  • 04 Feb 2022 This trial has been completed in Germany (Date of the global end of the trial : 31-Dec-2021), according to European Clinical Trials Database record.
  • 18 Jan 2022 Status changed from active, no longer recruiting to completed.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top